Teva launches first generic Lipitor in UK
May 8, 2012Sales and Marketing Lipitor, NHS, Pfizer, Teva, atorvastatin
Teva has launched the first generic Lipitor in the UK on the day the drug loses its patent protection. The …
Novartis ponders Lucentis price cut in UK
May 8, 2012Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access
Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …
BASF to build plant in US
May 8, 2012Manufacturing and Production BASF, Taylor, manufacturing, production
BASF has said it plans to build a new manufacturing facility for formic acid at its production site in Louisiana, …
DSM sees green shoots for pharma unit in Q1
May 8, 2012Business Services, Manufacturing and Production, Sales and Marketing DSM, Kensey Nash, NSCLC, Q1, Sinochem
DSM said its pharmaceutical business unit posted ‘weak’ financials in the first quarter of 2012, although revenues rose and there …
Genzyme boosts capacity following green light for Waterford plant
May 8, 2012Manufacturing and Production EMA, FDA, Genzyme, Sanofi, Waterford
Sanofi subsidiary Genzyme has doubled its capacity to fill-and-finish two of its drugs for rare disorders following approval of a …
ABPI to help pharma with digital communications
May 4, 2012Medical Communications ABPI, Code breach, PMCPA, Shire, digital, pharma
The ABPI has set up a new group to help pharma with its online communications. The UK industry body said …
GSK signs deal with academics
May 4, 2012Research and Development, Sales and Marketing Cancer, GSK, PROTAC, Yale, academia
GlaxoSmithKline has forged another link with academia, signing a deal with Yale University to design a potential new class of …
David Colin Thomé named as new Primary Care Commissioning chair
May 4, 2012Business Services, Sales and Marketing NHS, PCC
Primary Care Commissioning (PCC) has appointed David Colin Thomé as chair with immediate effect. Professor Thomé was until recently …
Novartis to acquire Fougera for $1.5 billion
May 3, 2012Sales and Marketing Fougera, Novartis, dermatology, generics, gilenya
Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash. Novartis’ generic unit Sandoz is conducting the …
Roche and Novartis have best websites
May 3, 2012Medical Communications Bowen Craggs & Co, Novartis, Pfizer, Roche, Shell, digital, web
A new survey of leading international companies has found Roche and Novartis have the best websites in the pharma sector. …
GSK appoints two non-executive directors to its Board
May 3, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Jing Ulrich, Lynn Elsenhans
GlaxoSmithKline has announced that Lynn Elsenhans and Jing Ulrich will join the Board of the Company with effect from 1 …
Oxford BioTherapeutics appoints new chief operations officer
May 3, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics
Oxford BioTherapeutics (OBT) has appointed Dr Esteban Pombo-Villar as its new chief operations officer (COO). In this position he will …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Professional regulation – a DIY job?
May 2, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPD, GMC, Les Rose, drug discovery, regulation
What would happen if we had no drug regulatory bodies, such as the MHRA and the EMA? Can you imagine …
Lilly invests in UK research base
May 2, 2012Research and Development Elil Lilly, Erl Wood, neuroscience
Eli Lilly has officially opened new research facilities at its R&D base in Erl Wood in Surrey.The site near Woking …
Lipitor losses hit Pfizer
May 2, 2012Sales and Marketing Alzheimer's, Lipitor, Pfizer, patent expiry
Lipitor’s US patent expiry has inflicted heavy damage on Pfizer’s revenues, with global sales down 7% in the first three …
SHL to speak & exhibit at the PDA’s upcoming Prefilled Syringe Seminar in Japan
May 2, 2012Manufacturing and Production auto injector, autoinjector, pda japan, prefilled syringe
SHL to speak & exhibit at the PDA’s upcoming Prefilled Syringe Seminar in Tokyo, Japan May 22nd-23rd 2012 Auto injectors …
Targacept cuts workforce
May 1, 2012Research and Development, Sales and Marketing AstraZeneca, MDD, TC-5214, Targecept
The fall-out from pipeline difficulties has led US biopharma company Targacept to make almost half its workforce redundant. In March …
EMA eSubmission Gateway now live
May 1, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing wainwright associates; ectd
Following a successful pilot, the European Medicines Agency (EMA) has announced that its eSubmission Gateway is now live for all …
Novartis will restart production at Lincoln plant in May
May 1, 2012Manufacturing and Production FDA, GMP, Lincoln, Nebraska, Novartis, manufacturing
Novartis chief executive Joe Jimenez has said that production at the firm’s troubled consumer health plant in Lincoln, Nebraska, will …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
AI: an early warning system for patient safety
